The Forxiga complex ‘Xigduo’ is approved, having high competitiveness in the market
As the complex of the first domestic SGLT-2(Sodium-Glucose Transport Proteins) inhibitor, ‘Forxiga(dapagliflozin),’ is about to be launched, the industry has paid attention to it.
According to the Ministiry of Food and Drug Safety on the 8th, the AstraZeneca’s SGLT-2 inhibitor complex ‘Xigduo 10...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
